• Explore /
  • Poster
  • / A randomized phase II trial comparing switch to nivolumab with TKI continuation after 12 weeks of TKI induction therapy in metastatic renal cell carcinoma patients (NIVOSWITCH).

A randomized phase II trial comparing switch to nivolumab with TKI continuation after 12 weeks of TKI induction therapy in metastatic renal cell carcinoma patients (NIVOSWITCH).

Abstract Poster

Authors

Viktor Grünwald

Viktor Grünwald

Innere Klinik und Klinik für Urologie, Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Essen, Germany

Viktor Grünwald , Carsten Grüllich , Philipp Ivanyi , Manfred Wirth , Peter Staib , Martin Schostak , Philip Dargatz , Lothar Müller , Michael Metz , Lothar Bergmann , Thomas Steiner , Manfred Welslau , Anja Lorch , Mohammad-Reza RAFIYAN , Eva Hellmis , Axel Hinke , Johannes Meiler , Thomas Kretz , Wolfgang C. Loidl , Anne Flörcken

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02959554

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 678)

Abstract #

678

Poster Bd #

F20

Abstract Disclosures

Similar Posters

First Author: Thomas Cosgriff

First Author: Robert Motzer

Poster

2024 ASCO Genitourinary Cancers Symposium

Erectile function in patients with metastatic renal cell carcinoma treated with first-line therapy.

Erectile function in patients with metastatic renal cell carcinoma treated with first-line therapy.

First Author: Ilya Tsimafeyeu

First Author: Audreylie Lemelin